Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Risks of adjuvant whole brain radiation therapy outweigh benefits for patients with limited brain metastases

Share :

2015 ASCO Annual Meeting
Published: 31 May 2015
Views: 2458
Rating:
Save
Dr Jan Buckner - Mayo Clinic, Rochester, USA

Dr Buckner presents, at a press conference at ASCO 2015,  a federally funded phase III trial that is providing additional information regarding a long-standing discussion about the impact of adjuvant whole brain radiation therapy (WBRT) on cognitive function.

Read the news article and watch the video interview for more.

Related Videos

Multiple Myeloma: evolving paradigm - Panel Discussion
Moderator: Dr Dibeyndu De/Panelists: Dr Amit Kumar, Dr Sunil Dharmani, Dr...
Multiple Myeloma: evolving paradigm - Panel Discussion ( Moderator: Dr Dibeyndu De/Panelists: Dr Amit Kumar, Dr Sunil Dharmani, Dr Siddharth Nanda AIIMS, Dr Avinash Tiwari, Dr Rudra Pratap, Dr Siddharth Turkar )
10 Oct 2024
ASCO 2024: Lung cancer highlights
Dr Antonio Passaro, Dr Matthew Krebs, Prof Raffaele Califano, Prof Nicolas...
ASCO 2024: Lung cancer highlights ( Dr Antonio Passaro, Dr Matthew Krebs, Prof Raffaele Califano, Prof Nicolas Girard and Dr Anna Minchom )
26 Jun 2024
Quality of life and patient satisfaction of Filipinos after breast conservation...
Dr Angeli Andrea Cocos-Alcantara - The Medical City, Pasig, Philippines
Quality of life and patient satisfaction of Filipinos after breast conservation surgery and intraoperative radiotherapy ( Dr Angeli Andrea Cocos-Alcantara - The Medical City, Pasig, Philippines )
12 Jun 2024
Multiple myeloma (A cancer arising from plasma cells)
Dr Nikesh Bajracharya - Civil Service Hospital, Kathmandu, Nepal
Multiple myeloma (A cancer arising from plasma cells) ( Dr Nikesh Bajracharya - Civil Service Hospital, Kathmandu, Nepal )
9 Nov 2023
2 year recurrence free survival benefit for resectable melanoma treated with...
Dr Sapna Patel - MD Anderson Cancer Center, Houston, USA
2 year recurrence free survival benefit for resectable melanoma treated with neoadjuvant/adjuvant pembrolizumab ( Dr Sapna Patel - MD Anderson Cancer Center, Houston, USA )
2 Nov 2023
Rationale for routine use of IORT for early breast cancer and data for specific...
Dr Hans-Christian Kolberg - Marienhospital Bottrop gGmbH, Bottrop, Germany
Rationale for routine use of IORT for early breast cancer and data for specific indications ( Dr Hans-Christian Kolberg - Marienhospital Bottrop gGmbH, Bottrop, Germany )
29 Jun 2023
Breast and emerging indications for IORT
Dr David Martinez Perez - AUNA, Lima, Peru
Breast and emerging indications for IORT ( Dr David Martinez Perez - AUNA, Lima, Peru )
26 Apr 2023
The advantages of IORT for early breast cancer treatment
Dr David Martinez Perez - AUNA, Lima, Peru
The advantages of IORT for early breast cancer treatment ( Dr David Martinez Perez - AUNA, Lima, Peru )
26 Apr 2023
The pros and cons of breast IORT and ultra hypofractionation (FR)
Dr Sofia Rivera - Institut Gustave Roussy, Villejuif, France
The pros and cons of breast IORT and ultra hypofractionation (FR) ( Dr Sofia Rivera - Institut Gustave Roussy, Villejuif, France )
4 Apr 2023

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation